Overview · Filed: Sep 13, 2024
UPC_CoA_528/2024
ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
AppealsMain AppealCourt of AppealAppealCase Closed
Parties
Claimants
- Amgen Inc.(Amgen Group)
Reps: Daniel Wise (Carpmaels & Ransford); Niels Hölder (Carpmaels & Ransford)
Respondents
- Sanofi-Aventis Deutschland GmbH(Sanofi Group)
- Sanofi-Aventis Groupe S.A.(Sanofi Group)
- Sanofi Winthrop Industrie S.A.(Sanofi Group)
- Regeneron Pharmaceuticals Inc.(Sanofi Group)
Reps: Koen Bijvank (Brinkhof N.V.); (Bardehle Pagenberg)
Judges
- Klaus Grabinski
- Nathalie Sabotier
- Peter Blok
Patents
- EP3666797
- EP 3 666 797
CPC codes: C07K2317/14, C07K2317/34, A61K39/395, A61K2039/505, A61K31/366, A61P3/06, A61K31/66, A61K31/22, A61P9/00, A61P7/00, A61P25/28, A61K2300/00…
Sector: Biotechnology
Outcome
Dismissed
Filed: Sep 13, 2024
First decided: Nov 25, 2025
Last decision: Mar 25, 2026
Language: English
The Court of Appeal (Panel with Klaus Grabinski, Nathalie Sabotier, Peter Blok) rejected Sanofi and Regeneron's application for suspensive effect concerning the Court of Appeal's own decision of 25 November 2025 which had rejected the requests for revocation of EP 3 666 797. Sanofi and Regeneron sought suspensive effect as part of a petition for rehearing (R. 220.4 RoP). The court found no basis to suspend a revocation-rejection decision (as this had no practical effect on the patent's validity status), and rejected the claim that the CoA's reasoning on claim interpretation and inventive step was based on issues not argued by the parties.
Open on UPC Registry